ArticleThe Journal of organic chemistry2018
Residual Complexity Does Impact Organic Chemistry and Drug Discovery: The Case of Rufomyazine and Rufomycin.
Article in The Journal of organic chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Multilevel Residual Complexity Analysis Reveals Origin of Nanomolar Antiviral Bioactives of "Isoquercitrin".Journal of natural products · 2026Article
- Enhancing rufomycin production by CRISPR/Cas9-based genome editing and promoter engineering inSynthetic and systems biotechnology · 2025Article
- Characterization of RufT Thioesterase Domain Reveals Insights into Rufomycin Cyclization and the Biosynthetic Origin of Rufomyazine.ACS chemical biology · 2025Article
- Preparation, Modification, Quantitation, and Dentin Biomodification Activity of Selectively Enriched Proanthocyanidins.Journal of natural products · 2025Article
- Article
- Advanced high-resolution chromatographic strategies for efficient isolation of natural products from complex biological matrices: from metabolite profiling to pure chemical entities.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2024Review
- New Rufomycins fromOrganic letters · 2022Article
- Pilot Study to Quantify Palladium Impurities in Lead-like Compounds Following Commonly Used Purification Techniques.ACS medicinal chemistry letters · 2022Article
- Investigation of red clover (Trifolium pratense) isoflavonoid residual complexity by off-line CCS-qHNMR.Fitoterapia · 2022Article
- Article
- Rufomycins or Ilamycins: Naming Clarifications and Definitive Structural Assignments.Journal of natural products · 2021Article
- Alkaloids in Contemporary Drug Discovery to Meet Global Disease Needs.Molecules (Basel, Switzerland) · 2021Review
- Bacterial terpenome.Natural product reports · 2021Review
- Natural products in drug discovery: advances and opportunities.Nature reviews. Drug discovery · 2021Review
- Isolation and Pharmacological Characterization of Six OpioidergicJournal of natural products · 2021Article
- Quantum mechanical NMR full spin analysis in pharmaceutical identity testing and quality control.Journal of pharmaceutical and biomedical analysis · 2021Review
- Semi-Synthesis of Marine-Derived Ilamycin F Derivatives and Their Antitubercular Activities.Frontiers in chemistry · 2021Article
- Isolation and Identification of Isocoumarin Derivatives With Specific Inhibitory Activity Against Wnt Pathway and Metabolome Characterization ofFrontiers in chemistry · 2021Article
- The Essential Medicinal Chemistry of Cannabidiol (CBD).Journal of medicinal chemistry · 2020Review
- Quantum Mechanics-Based Structure Analysis of Cyclic Monoterpene Glycosides fromJournal of natural products · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
Residual complexity (RC) involves the impact of subtle but critical structural and biological features on drug lead validation, including unexplained effects related to unidentified impurities. RC commonly plagues drug discovery efforts due to the inherent imperfections of chromatographic separation methods. The new diketopiperazine, rufomyazine (6), and the previously known antibiotic, rufomycin (7), represent a prototypical case of RC that (almost) resulted in the misassignment of biological activity. The case exemplifies that impurities well below the natural abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.